Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves once each week. In newly released clinical trial data, Amgen’s once-monthly ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...